Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review

2015 ◽  
Vol 35 (9) ◽  
pp. 823-837 ◽  
Author(s):  
Jordan B. King ◽  
Adam P. Bress ◽  
Austin D. Reese ◽  
Mark A. Munger
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Clinical Review ◽  
Reduced Ejection Fraction ◽  
Neprilysin Inhibition

Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction

Herz ◽  
2019 ◽  
Author(s):  
Sercan Okutucu ◽  
Sefik Gorkem Fatihoglu ◽  
Cengiz Sabanoglu ◽  
Nurbanu Bursa ◽  
Begum Yetis Sayin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Wave Dispersion ◽  
P Wave ◽  
Angiotensin Receptor ◽  
P Wave Dispersion ◽  
Reduced Ejection Fraction ◽  
Neprilysin Inhibition

Heart Failure with Preserved Ejection Fraction – A Review

2012 ◽  
Vol 9 (1) ◽  
pp. 90-95 ◽  
Author(s):  
Otto A Smiseth ◽  
Anders Opdahl ◽  
Espen Boe ◽  
Helge Skulstad
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Diastolic Heart Failure ◽  
The Elderly ◽  
Left Ventricular ◽  
Filling Pressure ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
Objective Evidence

Heart failure with preserved left ventricular ejection fraction (HF-PEF), sometimes named diastolic heart failure, is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase stroke volume by the Frank-Starling mechanism. LV interaction with stiff arteries aggravates these problems. Prognosis is almost as severe as for heart failure with reduced ejection fraction (HF-REF), in part reflecting co-morbidities. Before the diagnosis of HF-PEF is made, non-cardiac etiologies must be excluded. Due to the non-specific nature of heart failure symptoms, it is essential to search for objective evidence of diastolic dysfunction which, in the absence of invasive data, is done by echocardiography and demonstration of signs of elevated LV filling pressure, impaired LV relaxation, or increased LV diastolic stiffness. Antihypertensive treatment can effectively prevent HF-PEF. Treatment of HF-PEF is symptomatic, with similar drugs as in HF-REF.

Sign in / Sign up

Export Citation Format

Share Document